Preparations to be administered for treating or preventing ischemic
diseases or arterial diseases which contain Hepatocyte growth factor (HGF) as an
active ingredient. The preparations provide such effect that HGF concentration
in an affected region to which HGF was administered is maintained, a half-life
is longer, a dose can be reduced, and other organs except the affected region are
less affected in comparison with intravenous administration.
